Reliable Biopharmaceutical Corp. manufactures and develops pharmaceutical ingredients. It offers products in various categories, including active product ingredients, nucleic acid chemistry, enzymes and natural products, carbohydrate chemistry and ultra pure biochemicals. Its products are used in generic injectable drugs which treat cancer, heart diseases, hypertension, anxiety and other serious and life threatening illnesses. The company was founded by Robert S. Vaters and William G. Ash in 1968 and is headquartered in St. Louis, MO.

Reliable Biopharmaceutical LLC, part of Avantor, Inc., is an American company involved in pharmaceutical preparations.

Jiangsu Medico Chemical Co., Ltd., established on 2016-01-22, Business scope includes chemicals,medicine,biology,Technology development in the fields of pesticides and chemicals,technology transfer,Technical consulting and related technical services;Purchase and sale of chemical products;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Thrombologic ApS provides medical research and develops therapeutics. The firm develops a new therapy for prevention and treatment of multiple organ failure in Intensive care unit (ICU) patients. The company was founded in December 2009 and is headquartered in Copenhagen, Denmark.

Apicore provides process R&D and API manufacturing services for the pharmaceutical industry worldwide. The company's specialty active pharmaceutical ingredients specialize in the manufacture of difficult to synthesize, high value, and other niches API's, enabling a wide range of customers in the generic medicine industry to avail products at market competitive costs used for custom synthesis for early phase pharmaceutical research and branded products.

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research & development, manufacture, and sale of pharmaceutical products as well as veterinary medicines. Its products include active pharmaceutical ingredients and generic drugs. The company was founded in 1956 and is headquartered in Taizhou, China.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The firm’s products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

Mylan Pharmaceuticals, Inc. develops and manufactures generic prescription products. Its product includes tablets, Fosamax, Sectral, Xanax, capsules, liquids, and transdermal patches. The company was founded in 1961 and is headquartered in Morgantown, WV.

Yantai Dongcheng Pharmaceutical Group Co., Ltd. (formerly known as “Yantai Dongcheng Biochemical Co., Ltd.) was established in 1998 and listed on the Shenzhen Stock Exchange (stock code: 002675) in May 2012. After over 20 years of development, Yantai Dongcheng Pharmaceutical Group Co., Ltd. has become a large pharmaceutical group covering four fields: biochemical APIs, finished dosage forms, nuclide drugs and healthy products, which integrates the research and development, production and sales of medicines. The Group controls more than 40 subsidiaries, including Yantai Dongcheng Beifang Pharmaceutical Co., Ltd., Yantai Dongcheng Dayang Pharmaceuticals Co., Ltd., Linyi Dongcheng Dongyuan Biological Engineering Co., Ltd., Zhongtai Biological Chemical Products Co., Ltd., Dong Cheng International (HongKong) Limited, Chengdu Yunke Pharmaceutical Co., Ltd., Shanghai GMS Pharmaceutical Co., Ltd., Shanghai Yi Tai Pharmaceutical Technology Company Ltd., JYAMS Ltd., etc. The Group has set up the R&D branches and offices in Beijing, Shanghai and Nanjing and over two thousand employees.

Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., established on 2001-08-31, Business scope includes pharmaceuticals,Research and Development of Disinfectants,production and sales(Operate according to the scope listed in the license,involved in the law,Do not operate if prohibited by laws and regulations,Operating with a license involved in operating with a license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Shanghai Zhenyuan Diagnostics Technology Co., Ltd., established on 2012-08-30, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Import and export;Technology Import and Export;Production of Class I Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:Disinfectant production(Free of Hazardous Chemicals);Production of Class II Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Nanjing Tianxiang Pharmaceutical Technology Co., Ltd., established on 2013-02-22, Business scope includes traditional Chinese medicine,Western medicine,biomedicine,Healthy food,Technical research on biochemical reagents,to develop,transfer,consult,;Chemical Products,cosmetic,Sales of instrumentation.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of heparin series products and preparations. Its products include Heparin Sodium, Heparin Calcium, Heparin Lithium, Heparinoid, LPW Heparins, Sodium Syaluronate. The company was founded on September 28, 2000 and is headquartered in Shijiazhuang, China.

Joincare Pharmaceutical Industry Group Co., Ltd (hereinafter called Joincare Pharmaceutical Group), growing out of Shenzhen Taitai Healthcare Food Co., Ltd, was established by the board chairman Zhu Baoguo in the year 1992. The leading position in the healthcare industry was established by “Taitai Oral Liquid”. The strategy of the company was in transition to enter pharmaceutical industry in 1995, and was renamed Shenzhen Taitai Pharmaceutical Co., Ltd. This transformation was successfully completed by the acquisition of Shenzhen Haibin Pharmaceutica Co., Ltd in 1997. In 1999, the company was renamed Shenzhen.

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Beijing Kangren Tang Pharmaceutical Co., Ltd. specializes in the research and production of particles more than 20 years of Chinese medicine formulations, stick formulations reforms to Chinese medicine theory as the foundation of traditional Chinese medicine decoction, formation and improve the "Ingredients ® " the formulation of reform ideas. In the "Ingredients ® experienced under the guidance of" the idea of 20-year study, completed the "Ingredients ® " production technology system and quality standard system of Chinese medicine formulations particles, was patented more than 40 in the process, laid the Beijing Conran Tang Pharmaceutical has the corporate characteristics of “Inheriting the essence of Chinese medicine culture and enjoying the innovation of Chinese medicine technology”.

Lunan Pharmaceutical Group is an Integrated pharmaceutical group, National innovative enterprise and National torch plan key high-tech enterprise that produces, researches and sells both traditional Chinese medicine, chemical medicine and bio-pharmaceutical medicinal products.

Liaoning Haisco Pharmaceutical Co., Ltd., established on 2005-05-19, Business scope includes production:Freeze-dried powder injection,Freeze-dried powder injection(hormones),small volume injection,powder injection(Cephalosporins),large volume injection,large volume injection(Multi-layer co-extrusion infusion bag),API[methylprednisolone succinate(hormones),arginine glutamate,Cinepazide Maleate),Sterile API(Cefmenoxime hydrochloride,Cefotiam Hydrochloride).Chemical materials(Excluding hazardous chemicals and controlled chemicals);Import and transfer of medical technology;R&D and production of formula food for special medical purposes;Import and export of goods and technology.Corporate Image Planning Service;Business Management Consulting Services;Production of pharmaceutical packaging materials.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Shenzhen Haibin Pharmaceutical Co., Ltd., a subsidiary of Joincare Pharmaceutical Group Industry Co., Ltd., is a Chinese company located in Shenzhen that manufactures and sells pharmaceutical products. You Guo Xie is the current CEO of the firm.